ResMed Inc. (NYSE:RMD) Shares Sold by American Century Companies Inc.

American Century Companies Inc. decreased its stake in ResMed Inc. (NYSE:RMD) by 10.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 161,369 shares of the medical equipment provider’s stock after selling 19,353 shares during the quarter. American Century Companies Inc. owned approximately 0.11% of ResMed worth $36,903,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Thrivent Financial for Lutherans increased its holdings in shares of ResMed by 12.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 6,952 shares of the medical equipment provider’s stock valued at $1,697,000 after purchasing an additional 755 shares in the last quarter. Intech Investment Management LLC purchased a new stake in ResMed in the 3rd quarter worth $244,000. Cerity Partners LLC raised its position in ResMed by 82.0% during the third quarter. Cerity Partners LLC now owns 13,686 shares of the medical equipment provider’s stock worth $3,341,000 after acquiring an additional 6,167 shares during the period. Summit Trail Advisors LLC lifted its holdings in ResMed by 15.6% during the third quarter. Summit Trail Advisors LLC now owns 1,497 shares of the medical equipment provider’s stock valued at $365,000 after purchasing an additional 202 shares in the last quarter. Finally, Fisher Asset Management LLC grew its position in shares of ResMed by 6.2% in the third quarter. Fisher Asset Management LLC now owns 26,727 shares of the medical equipment provider’s stock valued at $6,525,000 after purchasing an additional 1,563 shares during the period. 54.98% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on RMD shares. UBS Group raised shares of ResMed from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 31st. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday. Morgan Stanley assumed coverage on shares of ResMed in a research note on Wednesday, March 19th. They set an “overweight” rating and a $280.00 price objective for the company. Stifel Nicolaus cut their price target on ResMed from $250.00 to $240.00 and set a “hold” rating for the company in a report on Wednesday, March 5th. Finally, Piper Sandler lifted their price objective on ResMed from $252.00 to $260.00 and gave the stock a “neutral” rating in a research report on Friday, January 31st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, ResMed currently has an average rating of “Moderate Buy” and an average target price of $249.73.

Insider Buying and Selling at ResMed

In other ResMed news, CEO Michael J. Farrell sold 8,009 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the sale, the chief executive officer now directly owns 455,472 shares in the company, valued at $107,842,105.44. This represents a 1.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the transaction, the director now owns 77,218 shares of the company’s stock, valued at approximately $18,695,249.98. This trade represents a 2.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,940 shares of company stock valued at $9,164,385 in the last three months. 0.71% of the stock is owned by corporate insiders.

ResMed Trading Up 0.3 %

Shares of RMD stock opened at $222.62 on Friday. ResMed Inc. has a 1-year low of $172.19 and a 1-year high of $263.05. The firm has a market cap of $32.69 billion, a PE ratio of 26.28, a price-to-earnings-growth ratio of 1.53 and a beta of 0.74. The company has a 50-day moving average of $234.10 and a two-hundred day moving average of $238.43. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. On average, analysts predict that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 13th were issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date was Thursday, February 13th. ResMed’s dividend payout ratio (DPR) is 25.03%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.